2019
DOI: 10.2147/cmar.s210029
|View full text |Cite
|
Sign up to set email alerts
|

<p>Histone deacetylase inhibitors reinforce the phenotypical markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties</p>

Abstract: IntroductionHistone deacetylase inhibitors (HDIs) are a group of compounds that exhibit anticancer activity, but their significance and usefulness in breast cancer (BC) treatment are still controversial. The ability of cancer cells to invade and migrate is augmented by the acquisition of a mesenchymal phenotype – a process known as epithelial-to-mesenchymal transition (EMT). Changes in the expression level of different cadherins, so-called cadherin switches, have been used to monitor the EMT process in develop… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
16
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9
1

Relationship

4
6

Authors

Journals

citations
Cited by 15 publications
(16 citation statements)
references
References 42 publications
0
16
0
Order By: Relevance
“…Although SAHA inhibited migration and proliferation of all analyzed BC cells in a time- and dose-dependent fashion, MDA-MB-468 cells with a more mesenchymal phenotype were found to overexpress mesenchymal markers (e.g., N-cadherin), whereas epithelial phenotype BC cells (T47D, MCF7) responded to SAHA treatment by an increase of epithelial markers (e.g., E-cadherin) expression. Therefore, induction of EMT or MET by SAHA is not a universal mechanism but cells- and context-dependent, and thus EMT should not be considered as the only measurement for tumor aggressiveness in BC ( Table 2 ) [ 111 ].…”
Section: Saha and Breast Cancermentioning
confidence: 99%
“…Although SAHA inhibited migration and proliferation of all analyzed BC cells in a time- and dose-dependent fashion, MDA-MB-468 cells with a more mesenchymal phenotype were found to overexpress mesenchymal markers (e.g., N-cadherin), whereas epithelial phenotype BC cells (T47D, MCF7) responded to SAHA treatment by an increase of epithelial markers (e.g., E-cadherin) expression. Therefore, induction of EMT or MET by SAHA is not a universal mechanism but cells- and context-dependent, and thus EMT should not be considered as the only measurement for tumor aggressiveness in BC ( Table 2 ) [ 111 ].…”
Section: Saha and Breast Cancermentioning
confidence: 99%
“…We also demonstrated additive type of pharmacological interactions between CDDP and SAHA or VPA at the fixed-ratio combination of 1:1 in TNBC cancer cell lines with increased or decreased Notch1 activity [ 18 ]. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay was used to evaluate antiproliferative effect of HDIs/CDDP treatment in the BC in vitro models, although previously [ 22 , 23 ] we showed by other methods the results of these drugs individually or/and in combinations on apoptosis [ 22 ], cell cycle arrest [ 22 ], and BrdU incorporation [ 23 ].…”
Section: Introductionmentioning
confidence: 99%
“…However, BC cells with the more mesenchymal phenotype (MDA-MB-468) were found to overexpress N-cadherin, whereas BC lines with an epithelial phenotype (T47D, MCF7) responded to HDI treatment through a significant increase in E-cadherin expression. Therefore, the authors conclude that HDI induction or reversal of EMT is not a universal mechanism, yet inhibition of cell migration is, and thus EMT should not be considered as the only measurement for tumor aggressiveness [ 64 ]. Taking into account the very divergent results regarding the influence of VPA on the EMT process this phenomenon should be thoroughly re-examined using the entire panel of BC cell lines and in vivo models ( Table 3 ).…”
Section: Valproic Acid and Breast Cancermentioning
confidence: 99%